CSL Limited (ASX: CSL)
The first blue chip ASX share to consider is CSL. It is one of the world’s leading biotechnology companies, comprising two businesses – CSL Behring and Seqirus. CSL Behring is the number one player in a global plasma therapies industry worth a massive US$30 billion per year. Whereas Seqirus is the number two player in the US$6 billion global influenza vaccines industry. CSL has been tipped for solid long term growth thanks to increasing demand for its therapies and its lucrative R&D pipeline.
UBS is positive on CSL. It currently has a buy rating and $330.00 price target on its shares.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$247.45 |
Change
-3.210(1.28%) |
Mkt cap ! $119.8B | |||
| Open | High | Low | Value | Volume |
| $250.60 | $251.00 | $245.46 | $183.9M | 744.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8 | $247.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $247.45 | 145 | 1 |
View Market Depth
| Last trade - 16.10pm 16/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |